98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

10 mM in DMSO

Cyclovirobuxine D increases cardiomyocytes viability injured by oxidation or hypoxia. It significantly reduces the infarct size induced by ligating the coronary artery in rats. In addition, Cyclovirobuxine D protects rat aorta endothelial cells against hypoxia and enhanced nitric oxide (NO) release from endothelial cells. Cyclovirobuxine D facilitates the utilization of intracellular Ca(2+) and prevents the loss of Ca(2+), which may be the underlying mechanism of its protective effect on heart failure.

Cyclovirobuxine D decreases the weight of venous thrombus in rats. Cyclovirobuxine D causes a primary effect of coronary vasodilatation in anesthetized pigs, which involves mechanisms related to the endothelial release of nitric oxide. In addition, Cyclovirobuxine D is beneficial for heart failure in rats induced by myocardial infarction. LD50: Mice 8.9mg/kg (i.v.), 9.2mg/kg (i.p.), 293mg/kg (i.g.).